Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Msc2360844
2. 1305267-37-1
3. Ioa244
4. Ioa-244
5. 6k8fc2tf54
6. Msc-2360844
7. [6-fluoro-1-[4-(morpholin-4-ylmethyl)phenyl]-5,5-dioxo-4h-thiochromeno[4,3-c]pyrazol-3-yl]-morpholin-4-ylmethanone
8. (6-fluoro-1,4-dihydro-1-(4-(4-morpholinylmethyl)phenyl)-5,5-dioxido(1)benzothiopyrano(4,3-c)pyrazol-3-yl)-4-morpholinylmethanone
9. [6-fluoro-1,4-dihydro-1-[4-(4-morpholinylmethyl)phenyl]-5,5-dioxido[1]benzothiopyrano[4,3-c]pyrazol-3-yl]-4-morpholinylmethanone
10. 6-fluoro-1-(4-((morpholin-4-yl)methyl)phenyl)-3-(morpholine-4-carbonyl)-1h,4h-5lambda6-thiochromeno(4,3-c)pyrazole-5,5-dione
11. 6-fluoro-1-{4-[(morpholin-4-yl)methyl]phenyl}-3-(morpholine-4-carbonyl)-1h,4h-5lambda6-thiochromeno[4,3-c]pyrazole-5,5-dione
12. Methanone, (6-fluoro-1,4-dihydro-1-(4-(4-morpholinylmethyl)phenyl)-5,5-dioxido(1)benzothiopyrano(4,3-c)pyrazol-3-yl)-4-morpholinyl-
13. Methanone, [6-fluoro-1,4-dihydro-1-[4-(4-morpholinylmethyl)phenyl]-5,5-dioxido[1]benzothiopyrano[4,3-c]pyrazol-3-yl]-4-morpholinyl-
14. Unii-6k8fc2tf54
15. Schembl12849
16. Chembl3683575
17. Bdbm169989
18. Nsc827886
19. Nsc-827886
20. Hy-135827
21. Cs-0114316
22. Us9073940, 339
| Molecular Weight | 526.6 g/mol |
|---|---|
| Molecular Formula | C26H27FN4O5S |
| XLogP3 | 1.3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 4 |
| Exact Mass | 526.16861931 g/mol |
| Monoisotopic Mass | 526.16861931 g/mol |
| Topological Polar Surface Area | 102 Ų |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 914 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
63
PharmaCompass offers a list of IOA-244 API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right IOA-244 manufacturer or IOA-244 supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred IOA-244 manufacturer or IOA-244 supplier.
PharmaCompass also assists you with knowing the IOA-244 API Price utilized in the formulation of products. IOA-244 API Price is not always fixed or binding as the IOA-244 Price is obtained through a variety of data sources. The IOA-244 Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Roginolisib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Roginolisib, including repackagers and relabelers. The FDA regulates Roginolisib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Roginolisib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Roginolisib supplier is an individual or a company that provides Roginolisib active pharmaceutical ingredient (API) or Roginolisib finished formulations upon request. The Roginolisib suppliers may include Roginolisib API manufacturers, exporters, distributors and traders.
Roginolisib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Roginolisib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Roginolisib GMP manufacturer or Roginolisib GMP API supplier for your needs.
A Roginolisib CoA (Certificate of Analysis) is a formal document that attests to Roginolisib's compliance with Roginolisib specifications and serves as a tool for batch-level quality control.
Roginolisib CoA mostly includes findings from lab analyses of a specific batch. For each Roginolisib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Roginolisib may be tested according to a variety of international standards, such as European Pharmacopoeia (Roginolisib EP), Roginolisib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Roginolisib USP).
